Compare DOMO & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMO | NKTX |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 477.0M | 129.3M |
| IPO Year | 2018 | 2020 |
| Metric | DOMO | NKTX |
|---|---|---|
| Price | $8.28 | $1.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $15.22 | $13.25 |
| AVG Volume (30 Days) | ★ 1.1M | 641.1K |
| Earning Date | 12-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $318,002,000.00 | N/A |
| Revenue This Year | $2.28 | N/A |
| Revenue Next Year | $2.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.01 | $1.31 |
| 52 Week High | $18.49 | $2.74 |
| Indicator | DOMO | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 30.40 | 52.06 |
| Support Level | $8.63 | $1.79 |
| Resistance Level | $9.22 | $1.90 |
| Average True Range (ATR) | 0.36 | 0.06 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 1.98 | 82.50 |
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.